PMC:7534795 / 21878-22118 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T161","span":{"begin":101,"end":119},"obj":"Chemical"},{"id":"T162","span":{"begin":124,"end":135},"obj":"Chemical"},{"id":"T163","span":{"begin":180,"end":198},"obj":"Chemical"}],"attributes":[{"id":"A161","pred":"chebi_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A162","pred":"chebi_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A163","pred":"chebi_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"}],"text":"elevated CRP, high D-dimer\n• Primary outcome of hospital discharge or clinical improvement\n• N = 86 methylprednisolone +/− tocilizumab\n• N = 86 standard care • Stage 1: Immediate methylprednisolone 250 mg i.v. on day 1, then 80 mg on days "}

{"project":"LitCovid-sentences","denotations":[{"id":"T149","span":{"begin":27,"end":90},"obj":"Sentence"},{"id":"T150","span":{"begin":91,"end":135},"obj":"Sentence"},{"id":"T151","span":{"begin":136,"end":169},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"elevated CRP, high D-dimer\n• Primary outcome of hospital discharge or clinical improvement\n• N = 86 methylprednisolone +/− tocilizumab\n• N = 86 standard care • Stage 1: Immediate methylprednisolone 250 mg i.v. on day 1, then 80 mg on days "}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T92","span":{"begin":0,"end":12},"obj":"Phenotype"}],"attributes":[{"id":"A92","pred":"hp_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/HP_0011227"}],"text":"elevated CRP, high D-dimer\n• Primary outcome of hospital discharge or clinical improvement\n• N = 86 methylprednisolone +/− tocilizumab\n• N = 86 standard care • Stage 1: Immediate methylprednisolone 250 mg i.v. on day 1, then 80 mg on days "}

{"project":"LitCovid-PubTator","denotations":[{"id":"655","span":{"begin":9,"end":12},"obj":"Gene"},{"id":"673","span":{"begin":101,"end":119},"obj":"Chemical"},{"id":"674","span":{"begin":124,"end":139},"obj":"Chemical"},{"id":"675","span":{"begin":180,"end":198},"obj":"Chemical"}],"attributes":[{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"Gene:1401"},{"id":"A673","pred":"tao:has_database_id","subj":"673","obj":"MESH:D008775"},{"id":"A675","pred":"tao:has_database_id","subj":"675","obj":"MESH:D008775"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"elevated CRP, high D-dimer\n• Primary outcome of hospital discharge or clinical improvement\n• N = 86 methylprednisolone +/− tocilizumab\n• N = 86 standard care • Stage 1: Immediate methylprednisolone 250 mg i.v. on day 1, then 80 mg on days "}